Probabilistic sensitivity analysis, societal perspective.

<p>Probabilistic sensitivity analysis, societal perspective.</p

Scenario analyses, societal perspective.

*<p>Mixed public and private incremental vaccine cost was calculated by weighing the public and private vaccine cost by the proportion of those who receive the vaccine at public cost.</p

<i>Tdap</i> waning vaccine efficacy.

<p><i>Tdap</i> waning vaccine efficacy.</p

Pertussis cases avoided by vaccinating 10% of US population aged 65 years.

<p>Pertussis cases avoided by vaccinating 10% of US population aged 65 years.</p

Incremental costs from vaccinating 10% of US population aged 65 years.

<p>Incremental costs from vaccinating 10% of US population aged 65 years.</p

Model inputs and sources for adults aged 65 years.

*<p>Vaccine cost was estimated as the incremental cost of Tdap versus Td and included drug acquisition cost and cost of vaccine adverse events (Lee 2007).</p>**<p>Cost is lost productivity per case and is applied to moderate and severe cases only.</p><p>PSA = probabilistic sensitivity analysis.</p

Incremental cost per case averted and per QALY gained (89% efficacy), societal perspective.

<p>Incremental cost per case averted and per QALY gained (89% efficacy), societal perspective.</p

Parameters in the Transmission Model.

<p>Parameters in the Transmission Model.</p

Economic model.

<p>Economic model.</p

Cases Avoided with Intervention Strategy, by Age Group, Case Severity, and Treatment.

<p>Cases Avoided with Intervention Strategy, by Age Group, Case Severity, and Treatment.</p